Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

By A. Menzies, Douglas B. Johnson, S. Ramanujam, V. Atkinson, Annie Wong, J. Park, J. McQuade, A. Shoushtari, K. Tsai, Z. Eroglu and 10 more. Annals of Oncology, 2016

748 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/0b0f5caa4af53a88a28747cdb06a5827d7254f83

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. C. Robert
3. K. Kerr
4. J. Haanen
5. J. Larkin
6. S. Peters
7. F. Carbonnel
8. M. Postow

Citations in the corpus

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “However, data suggest that they may be safely treated.(31,129) Indeed, a systematic review of case reports of patients with preexisting autoimmune diseases treated with ICPis found that 40%”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Patients with a history of autoimmune disease, or who are being actively treated for an autoimmune disease, are at risk for worsening of their autoimmune disease while on immune checkpoint blockade [16].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Patients with a history of autoimmune disease, or who are being actively treated for an autoimmune disease, are at risk for worsening of their autoimmune disease while on immune checkpoint blockade [16].”